Entering text into the input field will update the search result below

Pierre Fabre to commercialize Urovant's overactive bladder treatment vibegron in Europe

Jul. 05, 2022 9:16 AM ETMYOVBy: Anuron Mitra, SA News Editor

Human Urinary System Bladder Anatomy

magicmine/iStock via Getty Images

  • Urovant Sciences and French pharmaceutical company Pierre Fabre Médicament have entered into a licensing agreement to commercialize oral treatment vibegron for overactive bladder (OAB) in the European Economic Area, UK and Switzerland.
  • Urovant is a unit

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.